Quoin Pharmaceuticals Ltd. (QNRX)
Quoin Pharmaceuticals develops topical drug candidates for rare genetic skin diseases, led by a lotion for Netherton Syndrome. It last closed at $3.48 on Nov 17, down 2.25% on the day. The average 12-month price target from 3 analysts is $17.33 (+398.1% from the last close), with a high of $20.00 and a low of $14.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell).
Key Stats
Last 12 monthsNot reported for this period.
From QNRX's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 3 analysts who set a price target on QNRX in the past 90 days. The average target is $17.33, with a high of $20.00 and a low of $14.00, compared with the last close of $3.48.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 19 | Canaccord Genuity | Initiated | Buy | $18 |
| Oct 12 | BTIG | Initiated | Buy | $14 |
| Sep 23 | Lake Street | Initiated | Buy | $20 |
| May 4 | LUCID CAPITAL MARKETS | Initiated | Buy | $30 |
Technical Analysis
The stock is 13% below its 20 day and 39% below its 50 day average. It is 64% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 35), near oversold. The nearest support is the swing low (Nov 6) at $3.45, and the nearest resistance the Pivot R1 at $3.64.
| RSI (14) | 34.68 | Weak, oversold below 30 | Neutral |
| MACD | -0.29 | Above its signal line | Bullish |
| Stochastic | 15.8 | Near the bottom of its range | Oversold |
| ADX (14) | 22.5 | Weak trend | |
| Williams %R | -83.2 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -180.2 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −11.9% | Change over 10 sessions | Bearish |
| ATR (14) | $0.33 | Typical daily range, 9.5% of price |
| RSI (14) | 38.22 | Weak, oversold below 30 | Neutral |
| MACD | -0.72 | Below its signal line | Bearish |
| Stochastic | 3.9 | Near the bottom of its range | Oversold |
| ADX (14) | 13.5 | No clear trend | |
| Williams %R | -95.4 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -104.3 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −48.8% | Change over 10 sessions | Bearish |
| ATR (14) | $1.22 | Typical daily range, 35.0% of price |
What happened before
See how QNRX did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How QNRX has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2016.
Whale Options Flow
90DNo whale options trades in QNRX in the last 90 days.
QNRX Institutional Ownership
Full report →- ▲20 buying vs 11 selling
- ▲Held by funds +2.0 pts
- ▲Funds holding +6
- ▲Superinvestors: 2 added, 0 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 25 | 19 | +31.6% |
| In funds' top 10 | 0 | 0 | – |
| Held by funds | 3.8% | 1.9% | +2.0 pts |
| New / increased | 15 / 5 | 1 / 9 | +100.0% |
| Reduced / sold out | 2 / 9 | 3 / 3 | +83.3% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether QNRX is in one of them and how their past QNRX trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered QNRX in an article yet. Here's the latest on the wider market.
About Quoin Pharmaceuticals
Quoin Pharmaceuticals is a specialty drug developer based in Ashburn, Virginia. It focuses on treatments for rare and orphan diseases that have few or no approved options. Its lead product candidate, QRX003, is a topical lotion in clinical testing for Netherton Syndrome, a rare genetic skin disease, and it is also being studied for other rare skin conditions. The company plans to sell its products to patients and healthcare providers in the United States, Europe and Japan, and works with distribution partners in other countries. It has not yet commercialized any products.
- Headquarters
- Ashburn, VA

